PMID- 25593898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2278-1668 (Print)
IS  - 2278-0513 (Electronic)
IS  - 2278-0513 (Linking)
VI  - 3
IP  - 1
DP  - 2014
TI  - New serum biomarkers for prostate cancer diagnosis.
PG  - 72-79
AB  - BACKGROUND: Prostate-specific antigen (PSA) is currently used as a biomarker for 
      diagnosis and management of prostate cancer (CaP). However, PSA typically lacks 
      the sensitivity and specificity desired of a diagnostic marker. OBJECTIVE: The 
      goal of this study was to identify an additional biomarker or a panel of 
      biomarkers that is more sensitive and specific than PSA in differentiating benign 
      versus malignant prostate disease and/or localized CaP versus metastatic CaP. 
      METHODS: Concurrent measurements of circulating interleukin-8 (IL-8), Tumor 
      necrosis factor-alpha (TNF-alpha) and soluble tumor necrosis factor-alpha receptors 1 
      (sTNFR1) were obtained from four groups of men: (1) Controls (2) with elevated 
      prostate-specific antigen with a negative prostate biopsy (elPSA_negBx) (3) with 
      clinically localized CaP and (4) with castration resistant prostate cancer. 
      RESULTS: TNF-alpha Area under the receiver operating characteristic curve (AUC = 
      0.93) and sTNFR1 (AUC = 0.97) were strong predictors of elPSA_negBx (vs. CaP). 
      The best predictor of elPSA_negBx vs CaP was sTNFR1 and IL-8 combined (AUC = 
      0.997). The strongest single predictors of localized versus metastatic CaP were 
      TNF-alpha (AUC = 0.992) and PSA (AUC = 0.963) levels. CONCLUSIONS: The specificity 
      and sensitivity of a PSA-based CaP diagnosis can be significantly enhanced by 
      concurrent serum measurements of IL-8, TNF-alpha and sTNFR1. In view of the concerns 
      about the ability of PSA to distinguish clinically relevant CaP from indolent 
      disease, assessment of these biomarkers in the larger cohort is warranted.
FAU - Chadha, Kailash C
AU  - Chadha KC
AD  - Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, 
      University at Buffalo, Buffalo, NY, USA.
FAU - Miller, Austin
AU  - Miller A
AD  - Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, 
      University at Buffalo, Buffalo, NY, USA.
FAU - Nair, Bindukumar B
AU  - Nair BB
AD  - Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, 
      University at Buffalo, Buffalo, NY, USA ; Department of Medicine, Division of 
      Allergy/Immunology and Rheumatology, University at Buffalo, Buffalo, NY, USA.
FAU - Schwartz, Stanley A
AU  - Schwartz SA
AD  - Department of Medicine, Division of Allergy/Immunology and Rheumatology, 
      University at Buffalo, Buffalo, NY, USA.
FAU - Trump, Donald L
AU  - Trump DL
AD  - Department of Medicine, Roswell Park Cancer Institute, University at Buffalo, 
      Buffalo, NY, USA.
FAU - Underwood, Willie
AU  - Underwood W
AD  - Department of Urologic Oncology, Roswell Park Cancer Institute, University at 
      Buffalo, Buffalo, NY, USA.
LA  - eng
GR  - P30 CA016056/CA/NCI NIH HHS/United States
GR  - U10 CA031946/CA/NCI NIH HHS/United States
GR  - U10 CA033601/CA/NCI NIH HHS/United States
GR  - U24 CA114725/CA/NCI NIH HHS/United States
GR  - R21 CA113950/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - Turkey
TA  - Clin Cancer Investig J
JT  - Clinical cancer investigation journal
JID - 101586887
PMC - PMC4292911
MID - NIHMS598305
OTO - NOTNLM
OT  - Castration resistant prostate cancer
OT  - interleukin-8
OT  - prostate cancer
OT  - prostate specific antigen
OT  - serum biomarker
OT  - tumor necrosis factor-alpha
COIS- Conflict of Interest: None declared.
EDAT- 2015/01/17 06:00
MHDA- 2015/01/17 06:01
PMCR- 2015/01/13
CRDT- 2015/01/17 06:00
PHST- 2015/01/17 06:00 [entrez]
PHST- 2015/01/17 06:00 [pubmed]
PHST- 2015/01/17 06:01 [medline]
PHST- 2015/01/13 00:00 [pmc-release]
AID - 10.4103/2278-0513.125802 [doi]
PST - ppublish
SO  - Clin Cancer Investig J. 2014;3(1):72-79. doi: 10.4103/2278-0513.125802.